Bedfont’s piCO Smokerlyzer involved in smoking cessation study at Maastricht University

The piCO Smokerlyzer® is being used in a study by the Maastricht University on the effectiveness of financial incentives and smoking cessation

Manufactured by second-generation family company, Bedfont Scientific Ltd., the piCO Smokerlyzer® is a breath analysis medical device used to help people quit smoking. It will be used in a clinical study at the Maastricht University to investigate whether or not a reward makes smoking cessation more effective.

Using the piCO Smoklyzer

Image credit: Bedfont Scientific

The project, CATCH (Continuous Abstinence Through Corporate Healthcare), run by Prof. Dr. C. P. van Schayck and Dr. G. E. Nagelhout, will take several Dutch companies partaking in Smoking Cessation programmes, however only half of the subjects will receive gift certificates for their efforts.

The Smokerlyzer® range is a series of carbon monoxide (CO) monitors that measures the harmful amount of CO that is inhaled from smoking, which can show how much a patient has been smoking, giving smoking cessation advisors an idea on the level of dependency that the smoker has.

Sinefuma, a Smokerlyzer® distributor for Bedfont, is the biggest smoking cessation company in the Netherlands. Marcel Clarijs, director at SineFuma, explains:

It is beautiful that we can work together with the university and participate in research to find how we can get more succesfull quitters. We ran the smoking cessation programme within this study and were able to provide them with useful Smokerlyzer® monitors so they can validate the success rates. This CATCH project consisted of about 60 group trainings with 50 different companies to help employees to quit smoking. Roughly 600 people participated in total and now over the next 3 years the university will do the research.

Jason Smith, Managing Director at Bedfont®, adds:

The Smokerlyzer® has been used globally for over 30 years now to help people quit smoking – it is quick, easy and non-invasive making it a valuable tool to monitor a quit attempt, as well as being a motivational visual aid to encourage the user to quit smoking. We are very proud that SineFuma has managed to involve the piCO™ Smokerlyzer® in this study and hopefully, through the research done by Maastricht University, we can help to find new methods and incentives to help people quit smoking successfully.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Bedfont® Scientific Ltd. (2020, May 11). Bedfont’s piCO Smokerlyzer involved in smoking cessation study at Maastricht University. News-Medical. Retrieved on April 23, 2024 from https://www.news-medical.net/news/20171011/Bedfonts-piCO-Smokerlyzer-involved-in-smoking-cessation-study-at-Maastricht-University.aspx.

  • MLA

    Bedfont® Scientific Ltd. "Bedfont’s piCO Smokerlyzer involved in smoking cessation study at Maastricht University". News-Medical. 23 April 2024. <https://www.news-medical.net/news/20171011/Bedfonts-piCO-Smokerlyzer-involved-in-smoking-cessation-study-at-Maastricht-University.aspx>.

  • Chicago

    Bedfont® Scientific Ltd. "Bedfont’s piCO Smokerlyzer involved in smoking cessation study at Maastricht University". News-Medical. https://www.news-medical.net/news/20171011/Bedfonts-piCO-Smokerlyzer-involved-in-smoking-cessation-study-at-Maastricht-University.aspx. (accessed April 23, 2024).

  • Harvard

    Bedfont® Scientific Ltd. 2020. Bedfont’s piCO Smokerlyzer involved in smoking cessation study at Maastricht University. News-Medical, viewed 23 April 2024, https://www.news-medical.net/news/20171011/Bedfonts-piCO-Smokerlyzer-involved-in-smoking-cessation-study-at-Maastricht-University.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Prioritising Lung Health: How FeNO can help to tackle Lung Conditions, the UK's 3rd Largest Threat